Cargando…

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

PURPOSE: Marginal zone lymphoma (MZL) is an uncommon non–Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Bruton tyrosine kinase inhibitor, in patients with relap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Opat, Stephen, Tedeschi, Alessandra, Linton, Kim, McKay, Pamela, Hu, Bei, Chan, Henry, Jin, Jie, Sobieraj-Teague, Magdalena, Zinzani, Pier Luigi, Coleman, Morton, Thieblemont, Catherine, Browett, Peter, Ke, Xiaoyan, Sun, Mingyuan, Marcus, Robert, Portell, Craig A., Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Mapp, Sally, Ho, Shir-Jing, Talaulikar, Dipti, Zhou, Ke-Shu, Co, Melannie, Li, Xiaotong, Zhou, Wenxiao, Cappellini, Massimo, Tankersley, Chris, Huang, Jane, Trotman, Judith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401507/ https://www.ncbi.nlm.nih.gov/pubmed/34526366 http://dx.doi.org/10.1158/1078-0432.CCR-21-1704

Ejemplares similares

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
por: Opat, Stephen, et al.
Publicado: (2023)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
por: Opat, S., et al.
Publicado: (2022)

P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL
por: Opat, Stephen, et al.
Publicado: (2023)

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
por: An, Gang, et al.
Publicado: (2021)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL
por: Tatarczuch, M., et al.
Publicado: (2022)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP
por: Huang, Qiu-Sha, et al.
Publicado: (2023)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
por: Wang, Liang, et al.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
por: Čermáková, Lucie, et al.
Publicado: (2022)

Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020)

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
por: Mu, Song, et al.
Publicado: (2019)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
por: Zhang, Heather, et al.
Publicado: (2021)

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
por: Tam, Constantine, et al.
Publicado: (2023)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
por: Rhodes, Joanna M, et al.
Publicado: (2021)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study
por: Cull, Gavin, et al.
Publicado: (2021)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
por: Silvestre, Antonio Salar, et al.
Publicado: (2023)

Mind Perception Is the Essence of Morality
por: Gray, Kurt, et al.
Publicado: (2012)

Neuroethics: A New Way of Doing Ethics
por: Levy, Neil
Publicado: (2011)

A Life Worth Giving? The Threshold for Permissible Withdrawal of Life Support From Disabled Newborn Infants
por: Wilkinson, Dominic James
Publicado: (2011)

Just How Cognitive Is “Cognitive Enhancement”? On the Significance of Emotions in University Students' Experiences with Study Drugs
por: Vrecko, Scott
Publicado: (2013)

Troubled sleep: Night waking, breastfeeding and parent–offspring conflict
por: Haig, David
Publicado: (2014)

Thinking Ahead on Deep Brain Stimulation: An Analysis of the Ethical Implications of a Developing Technology
por: Johansson, Veronica, et al.
Publicado: (2014)

Brave New Love: The Threat of High-Tech “Conversion” Therapy and the Bio-Oppression of Sexual Minorities
por: Earp, Brian D., et al.
Publicado: (2014)

Patient and Citizen Participation in Health: The Need for Improved Ethical Support
por: Williamson, Laura
Publicado: (2014)

Ethics of Clinical Science in a Public Health Emergency: Drug Discovery at the Bedside
por: Edwards, Sarah J. L.
Publicado: (2013)

Treating Patients as Persons: A Capabilities Approach to Support Delivery of Person-Centered Care
por: Entwistle, Vikki A., et al.
Publicado: (2013)

The Use of Deception in Public Health Behavioral Intervention Trials: A Case Study of Three Online Alcohol Trials
por: McCambridge, Jim, et al.
Publicado: (2013)

If I Could Just Stop Loving You: Anti-Love Biotechnology and the Ethics of a Chemical Breakup
por: Earp, Brian D., et al.
Publicado: (2013)

A Threat to Autonomy? The Intrusion of Predictive Brain Implants
por: Gilbert, Frederic
Publicado: (2015)

A prospective study of macrophage migration inhibitory factor as a marker of inflammatory detection
por: Zhang, Chao, et al.
Publicado: (2009)

Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework
por: Evitt, Niklaus H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cmi0susvo3md5b78mmdvm99bhr